Viridian Therapeutics (VRDN) Competitors

$17.43 +0.39 (+2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$17.48 +0.05 (+0.29%)

As of 04:45 PM Eastern

VRDN vs. HIMS, CELC, PACS, CAI, and RDNT

Should you buy Viridian Therapeutics stock or one of its competitors? MarketBeat compares Viridian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viridian Therapeutics include Hims & Hers Health (HIMS), Celcuity (CELC), PACS Group (PACS), Caris Life Sciences (CAI), and RadNet (RDNT). These companies are all part of the "healthcare" industry.

How does Viridian Therapeutics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

In the previous week, Hims & Hers Health had 51 more articles in the media than Viridian Therapeutics. MarketBeat recorded 73 mentions for Hims & Hers Health and 22 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.85 beat Hims & Hers Health's score of 0.02 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	16 Very Positive mention(s)	11 Positive mention(s)	9 Neutral mention(s)	24 Negative mention(s)	5 Very Negative mention(s)	Neutral
Viridian Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.5% of Hims & Hers Health shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hims & Hers Health has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Hims & Hers Health has a net margin of -0.56% compared to Viridian Therapeutics' net margin of -490.31%. Hims & Hers Health's return on equity of 6.10% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Hims & Hers Health has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.35	$128.37M	$0.51	47.52
Viridian Therapeutics	$70.85M	25.32	-$342.60M	-$3.32	N/A

Hims & Hers Health currently has a consensus price target of $29.50, indicating a potential upside of 21.73%. Viridian Therapeutics has a consensus price target of $37.43, indicating a potential upside of 115.06%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Hims & Hers Health beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Viridian Therapeutics had 14 more articles in the media than Celcuity. MarketBeat recorded 22 mentions for Viridian Therapeutics and 8 mentions for Celcuity. Celcuity's average media sentiment score of 1.28 beat Viridian Therapeutics' score of 0.85 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Viridian Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Celcuity has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Celcuity has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -490.31%. Viridian Therapeutics' return on equity of -80.19% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-203.17%	-52.68%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Celcuity has higher earnings, but lower revenue than Viridian Therapeutics. Celcuity is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.79	N/A
Viridian Therapeutics	$70.85M	25.32	-$342.60M	-$3.32	N/A

Celcuity currently has a consensus price target of $134.50, indicating a potential downside of 0.25%. Viridian Therapeutics has a consensus price target of $37.43, indicating a potential upside of 115.06%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Viridian Therapeutics beats Celcuity on 10 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to PACS Group?

PACS Group (NYSE:PACS) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

PACS Group has a net margin of 4.49% compared to Viridian Therapeutics' net margin of -490.31%. PACS Group's return on equity of 26.47% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

PACS Group has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.43B	1.16	$191.54M	$1.56	25.46
Viridian Therapeutics	$70.85M	25.32	-$342.60M	-$3.32	N/A

PACS Group currently has a consensus price target of $45.60, indicating a potential upside of 14.80%. Viridian Therapeutics has a consensus price target of $37.43, indicating a potential upside of 115.06%. Given Viridian Therapeutics' higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Viridian Therapeutics had 9 more articles in the media than PACS Group. MarketBeat recorded 22 mentions for Viridian Therapeutics and 13 mentions for PACS Group. PACS Group's average media sentiment score of 1.06 beat Viridian Therapeutics' score of 0.85 indicating that PACS Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PACS Group has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Summary

PACS Group beats Viridian Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to Caris Life Sciences?

Viridian Therapeutics (NASDAQ:VRDN) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Caris Life Sciences has a net margin of 3.75% compared to Viridian Therapeutics' net margin of -490.31%. Caris Life Sciences' return on equity of 98.28% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Caris Life Sciences	3.75%	98.28%	48.87%

Caris Life Sciences has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	25.32	-$342.60M	-$3.32	N/A
Caris Life Sciences	$812.03M	5.29	-$68.09M	-$7.61	N/A

Viridian Therapeutics presently has a consensus price target of $37.43, indicating a potential upside of 115.06%. Caris Life Sciences has a consensus price target of $27.56, indicating a potential upside of 81.24%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Caris Life Sciences had 4 more articles in the media than Viridian Therapeutics. MarketBeat recorded 26 mentions for Caris Life Sciences and 22 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.85 beat Caris Life Sciences' score of 0.16 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Caris Life Sciences beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to RadNet?

Viridian Therapeutics (NASDAQ:VRDN) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

77.9% of RadNet shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 5.6% of RadNet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

RadNet has a net margin of -0.66% compared to Viridian Therapeutics' net margin of -490.31%. RadNet's return on equity of 2.77% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
RadNet	-0.66%	2.77%	0.97%

RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	25.32	-$342.60M	-$3.32	N/A
RadNet	$2.04B	2.06	-$18.65M	-$0.18	N/A

Viridian Therapeutics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, RadNet has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

In the previous week, Viridian Therapeutics had 9 more articles in the media than RadNet. MarketBeat recorded 22 mentions for Viridian Therapeutics and 13 mentions for RadNet. Viridian Therapeutics' average media sentiment score of 0.85 beat RadNet's score of 0.31 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RadNet	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viridian Therapeutics presently has a consensus price target of $37.43, indicating a potential upside of 115.06%. RadNet has a consensus price target of $88.14, indicating a potential upside of 64.96%. Given Viridian Therapeutics' higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

RadNet beats Viridian Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-5.24	18.81	20.87	25.61
Price / Sales	25.32	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.56	6.75	9.86	6.71
Net Income	-$342.60M	$24.11M	$3.55B	$333.77M
7 Day Performance	2.40%	0.11%	-0.26%	0.40%
1 Month Performance	14.58%	0.87%	1.39%	4.03%
1 Year Performance	40.58%	78.18%	41.07%	36.33%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	3.8832 of 5 stars	$17.43 +2.3%	$37.43 +114.7%	+33.0%	$1.80B	$70.85M	N/A	50	Analyst Forecast Insider Trade Gap Up
HIMS Hims & Hers Health	4.2021 of 5 stars	$29.12 +3.0%	$31.86 +9.4%	-62.3%	$6.44B	$2.35B	57.10	2,442	Trending News Earnings Report Analyst Forecast Options Volume
CELC Celcuity	1.8383 of 5 stars	$125.64 -4.1%	$134.50 +7.1%	+1,050.4%	$6.34B	N/A	N/A	40	Positive News
PACS PACS Group	3.6216 of 5 stars	$32.06 -4.6%	$44.40 +38.5%	+277.1%	$5.28B	$5.29B	26.06	47,455	Earnings Report Analyst Forecast
CAI Caris Life Sciences	4.3621 of 5 stars	$15.94 -1.3%	$27.56 +72.9%	N/A	$4.56B	$812.03M	N/A	1,846	Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. HIMS, CELC, PACS, CAI, and RDNT

How does Viridian Therapeutics compare to Hims & Hers Health?

Summary

How does Viridian Therapeutics compare to Celcuity?

Summary

How does Viridian Therapeutics compare to PACS Group?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Summary

How does Viridian Therapeutics compare to RadNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. HIMS, CELC, PACS, CAI, and RDNT

How does Viridian Therapeutics compare to Hims & Hers Health?

Does the media favor HIMS or VRDN?

Do insiders & institutionals have more ownership in HIMS or VRDN?

Which has more volatility & risk, HIMS or VRDN?

Is HIMS or VRDN more profitable?

Which has preferable valuation & earnings, HIMS or VRDN?

Do analysts recommend HIMS or VRDN?

Summary

How does Viridian Therapeutics compare to Celcuity?

Does the media refer more to CELC or VRDN?

Do institutionals & insiders have more ownership in CELC or VRDN?

Which has more volatility & risk, CELC or VRDN?

Is CELC or VRDN more profitable?

Which has higher earnings and valuation, CELC or VRDN?

Do analysts rate CELC or VRDN?

Summary

How does Viridian Therapeutics compare to PACS Group?

Is PACS or VRDN more profitable?

Which has higher earnings and valuation, PACS or VRDN?

Do analysts rate PACS or VRDN?

Does the media prefer PACS or VRDN?

Which has more volatility & risk, PACS or VRDN?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Is VRDN or CAI more profitable?

Which has stronger earnings & valuation, VRDN or CAI?

Do analysts rate VRDN or CAI?

Does the media prefer VRDN or CAI?

Summary

How does Viridian Therapeutics compare to RadNet?

Do insiders and institutionals have more ownership in VRDN or RDNT?

Is VRDN or RDNT more profitable?

Which has stronger earnings & valuation, VRDN or RDNT?

Which has more risk & volatility, VRDN or RDNT?

Does the media prefer VRDN or RDNT?

Do analysts rate VRDN or RDNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools